| ||||||||||||||
|
|
|||||||||||||

*New Drug Center at Amphastar Pharmaceuticals Inc., Rancho Cucamonga, California; and
Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Address correspondence and reprint requests to Paul F. White, PhD, MD, Department of Anesthesiology and Pain Management, 5323 Harry Hines Blvd., Dallas, TX 753909068. Address e-mail to paul.white{at}utsouthwestern.edu
Controversy surrounds the use of the antiemetic droperidol, because of the Food and Drug Administration-imposed "black box" warning alleging that even small doses of the drug can lead to serious (even fatal) arrhythmias when it is used for antiemetic prophylaxis during the perioperative period. We used mathematical modeling of electrocardiographic QT interval data published in a peer-reviewed manuscript to evaluate the relationship between the dose of droperidol (0.10.25 mg/kg IV) and QTc prolongation. In comparing the calculated QTc values based on the logarithm model (2763 ms), the linear model (2767 ms) and the square-root model (3657 ms) to the actual measured QTc values (3759 ms), the square-root model provided the best simulation of the experimental findings. Other models that we evaluated included the polynomial model and various exponent models (e.g., quartic-root model, cubic-root model, square model, and cubic model). The estimated median prolongation of the median QTc interval produced by droperidol 0.6251.25 mg IV would vary from 9 ± 3 to 18 ± 3 ms. Therefore, this regression analysis suggests that small "antiemetic" doses of droperidol (
1.25 mg) would be unlikely to produce proarrhythmogenic effects in the perioperative period.
IMPLICATIONS: Using a square-root curve fit model to evaluate the relationship between the dose of droperidol and QTc prolongation, small-dose droperidol (0.6251.25 mg IV) would be expected to produce <30-ms prolongation of the QTc interval. Therefore, small "antiemetic" doses of droperidol would not be expected to produce proarrhythmogenic effects when used for prophylaxis in surgical patients.
This article has been cited by other articles:
![]() |
S. Yalcyn, B. Yalcyn, A. Buyukcelik, F. Hartig, C. Pechlaner, C. C. Apfel, and D. I. Sessler Prevention of Postoperative Nausea and Vomiting N. Engl. J. Med., September 30, 2004; 351(14): 1458 - 1459. [Full Text] [PDF] |
||||
![]() |
P. F. White Prevention of Postoperative Nausea and Vomiting -- A Multimodal Solution to a Persistent Problem N. Engl. J. Med., June 10, 2004; 350(24): 2511 - 2512. [Full Text] [PDF] |
||||
|